Overview

• The deal values SIFI’s enterprise at €270 million and brings three business lines on board: ophthalmology, third-party manufacturing and the newly approved therapy Akantior.
• SIFI, with over 90 years of history, reported about €100 million in base ophthalmology revenues and €20 million in EBITDA in 2024.
• Combined with the earlier Edol purchase, ophthalmology is set to represent roughly 20% of Faes Farma’s total income.
• Earn-outs of up to €50.5 million are linked to commercial milestones for Akantior, which has been approved in Europe for the treatment of ultra-rare diseases.
• The acquisition secures direct market entry into Italy, France, Romania and Turkey while reinforcing Faes Farma’s presence in Spain and Mexico.